Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells

• Status: Terminated
• Trial end date: 2021-09-01

Summary

This phase II trial studies the efficacy of trastuzumab treatment in breast cancer patients with stage II-III human epidermal growth factor receptor 2 (HER2)-negative tumors and HER2-expressing bone marrow disseminated tumor cells. Administering targeted trastuzumab therapy to these patients may result in the elimination of HER2 expressing disseminated tumor cells and improved disease free survival.

• Phase: Phase 2

Details

• Lead Sponsor: Washington University School of Medicine
• Collaborator: Genentech, Inc.
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Cyclophosphamide; Docetaxel; Doxorubicin; Epirubicin; Fluorouracil; Liposomal doxorubicin; Paclitaxel; Trastuzumab